Form 4: Vivo Opportunity Increases Stake in InMed Pharmaceuticals

Vivo Opportunity, LLC has reported a series of open market purchases increasing its beneficial ownership in InMed Pharmaceuticals Inc.

Summary

• Vivo Opportunity, LLC and its affiliated funds acquired a total of 175,560 common shares of InMed Pharmaceuticals Inc. (INM) between May 20, 2026, and June 8, 2026.
• The acquisitions were made through open market transactions at weighted average prices ranging from $1.52 to $1.69 per share.
• Following these transactions, the reporting entities increased their aggregate beneficial ownership to 790,979 common shares.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive signal, as sustained open-market buying by a 10% owner typically reflects strong conviction in the issuer's underlying value.

Positives

• Significant insider/major shareholder accumulation indicates confidence in the company's long-term prospects.
• Consistent buying activity across multiple dates suggests a strategic increase in position rather than a one-off trade.

Negatives

• The accumulation of shares by a 10% owner can sometimes signal potential future activist involvement or pressure on management.

Risks

• Market volatility affecting the share price of small-cap pharmaceutical companies.
• Reliance on the continued support of major institutional shareholders.

Future Outlook

No specific forward-looking guidance regarding company operations was provided; the filing is strictly a disclosure of changes in beneficial ownership.

Industry Context

StockSavvy.ai notes that increased accumulation by institutional investors in the pharmaceutical sector often precedes strategic shifts or reflects a belief that the stock is currently undervalued relative to its clinical pipeline or market potential.

Comparison to Industry Standards

• The purchase activity is consistent with standard institutional portfolio rebalancing for small-cap biotech holdings.
• The price paid per share aligns with recent market trading ranges for similar micro-cap pharmaceutical equities.

Stakeholder Impact

• Shareholders may view the increased stake as a vote of confidence in the company's direction.
• Potential for increased influence by Vivo Opportunity on future corporate decisions.

Next Steps

• Continued monitoring of SEC filings for further changes in beneficial ownership by Vivo Opportunity.
• Observation of potential impact on future shareholder voting or corporate governance.

Key Dates

Recommendation

While insider/major shareholder buying is a bullish indicator, this filing represents a change in ownership structure rather than a fundamental change in the company's business operations, warranting a hold until further operational catalysts emerge.

Keywords

InMed Pharmaceuticals, INM, Vivo Opportunity, Insider Buying, Beneficial Ownership, SEC Form 4